Barbara Dalton has worked at Pfizer’s corporate venturing unit for the past six years as vice-president.
She joined Pfizer from EuclidSR Partners, a venture firm backed by UK-based pharmaceutical company GlaxoSmithKline, where she worked from 2000 to 2007. Before this she was at GlaxoSmithKline’s corporate venturing unit SR One for seven years. Dalton has a PhD in microbiology and immunology from Medical College of Pennsylvania.
She said: “We use a fund-of-funds strategy to expand our reach in developing geographies in Africa, Brazil and China. In addition to traditional venture capital investments we are exploring and supporting other investment models – consortium, product development deals, corporate spin-outs.”
